Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Shocking muscles back to health: could zaps help seniors recover from lung illness?

NCT ID NCT05452226

Knowledge-focused Sponsor: University of Vermont Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether using a device that sends mild electrical pulses to the leg muscles (NMES) could help older adults recover strength and mobility after being hospitalized for a COPD flare-up or pneumonia. Seven participants used the device in the hospital and at home for six weeks. The main goal was to see if the treatment was practical and acceptable, not yet to prove it works.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
neuromuscular electrical stimulation (NMES) device
What this could lead to
If successful, this approach could provide a simple, at-home way to help older adults regain strength and mobility after a serious lung illness.
What could go wrong
This was a very small, early feasibility study with only 7 participants. It was not designed to prove effectiveness, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

7 people

The number who actually took part.

Started

Jul 2022

Finished

Dec 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. \>50 years old 2. Hospitalized for CAP and/or AECOPD 3. Expected hospital stay \>2 days after enrollment (to permit adequate application of and training in NMES) Exclusion Criteria: 1. \>7 days of hospitalization prior to enrollment 2. Life expectancy \< 6 months 3. Clinical Frailty Scale87 score \>6 4. Lower extremity impairments that prevent bilateral use of NMES (e.g., amputation, leg injury) 5. Acute lower extremity deep vein thrombosis 6. Implanted cardioverter-defibrillator or pacemaker 7. Body mass index (BMI) \>40 kg/m2 8. Currently requiring ICU care (including for sepsis)90. Prior ICU care during this hospitalization acceptable. 9. Severe skin breakdown on either lower extremity 10. Not ambulating independently prior to admission (gait aid is permitted) 11. New or existing intracranial, spinal, vascular, or neuromuscular condition limiting walking ability 12. Language barrier prohibiting outcome assessment 13. More than mild pre-existing dementia (IQCODE\* score \>3.6) 14. Likely discharge to setting where study team cannot oversee/monitor intervention (e.g., skilled nursing facility where team cannot monitor compliance) 15. Incarcerated 16. Refuses informed consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Community-acquired pneumonia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic obstructive pulmonary disease Community-Acquired Pneumonia pneumonia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Community-acquired pneumonia COPD exacerbation acute

Contacts and locations

Locations

  • University of Vermont

    Burlington, Vermont, 05405, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.